Stock Track | Roivant Sciences Soars 9.93% in Pre-market on Positive Phase 2 Results for Brepocitinib

Stock Track02-06 20:09

Roivant Sciences Ltd. (ROIV) experienced a significant pre-market surge of 9.93% on Friday. The sharp upward movement follows the release of encouraging clinical trial data from one of its subsidiary companies.

Priovant Therapeutics, a company within the Roivant Sciences family, announced positive results from its Phase 2 BEACON study evaluating brepocitinib for the treatment of cutaneous sarcoidosis. The study reported that 100% of patients receiving the 45 mg dose showed improvement, and the drug was well tolerated with no serious adverse events. This marks the first industry-sponsored placebo-controlled trial in this condition to report positive results, with plans to advance to a Phase 3 program in 2026.

The promising clinical data for brepocitinib appears to have driven investor optimism, overshadowing the company's concurrent release of its third-quarter financial results, which included a net loss.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130252803?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130252803","market":"hk","top_or_hot":-1,"title":"Stock Track | Roivant Sciences Soars 9.93% in Pre-market on Positive Phase 2 Results for Brepocitinib","media":"Stock Track","content":"<p>Roivant Sciences Ltd. (ROIV) experienced a significant pre-market surge of 9.93% on Friday. The sharp upward movement follows the release of encouraging clinical trial data from one of its subsidiary companies.</p><p>Priovant Therapeutics, a company within the Roivant Sciences family, announced positive results from its Phase 2 BEACON study evaluating brepocitinib for the treatment of cutaneous sarcoidosis. The study reported that 100% of patients receiving the 45 mg dose showed improvement, and the drug was well tolerated with no serious adverse events. This marks the first industry-sponsored placebo-controlled trial in this condition to report positive results, with plans to advance to a Phase 3 program in 2026.</p><p>The promising clinical data for brepocitinib appears to have driven investor optimism, overshadowing the company's concurrent release of its third-quarter financial results, which included a net loss.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Roivant Sciences Soars 9.93% in Pre-market on Positive Phase 2 Results for Brepocitinib</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Roivant Sciences Soars 9.93% in Pre-market on Positive Phase 2 Results for Brepocitinib\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-06 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Roivant Sciences Ltd. (ROIV) experienced a significant pre-market surge of 9.93% on Friday. The sharp upward movement follows the release of encouraging clinical trial data from one of its subsidiary companies.</p><p>Priovant Therapeutics, a company within the Roivant Sciences family, announced positive results from its Phase 2 BEACON study evaluating brepocitinib for the treatment of cutaneous sarcoidosis. The study reported that 100% of patients receiving the 45 mg dose showed improvement, and the drug was well tolerated with no serious adverse events. This marks the first industry-sponsored placebo-controlled trial in this condition to report positive results, with plans to advance to a Phase 3 program in 2026.</p><p>The promising clinical data for brepocitinib appears to have driven investor optimism, overshadowing the company's concurrent release of its third-quarter financial results, which included a net loss.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ROIV","symbol_name":"Roivant Sciences Ltd.","start_time":0,"source_url":"","article_id":"1130252803","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130252803","pubTimestamp":1770379741,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Roivant Sciences Ltd. (ROIV) experienced a significant pre-market surge of 9.93% on Friday. The sharp upward movement follows the release of encouraging clinical trial data from one of its subsidiary...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ROIV":"Roivant Sciences Ltd."},"translate_title":"股票追踪|Roivant Sciences盘前大涨9.93%brepocitinib 2期结果积极","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROIV":1},"content_text":"Roivant Sciences Ltd. (ROIV) experienced a significant pre-market surge of 9.93% on Friday. The sharp upward movement follows the release of encouraging clinical trial data from one of its subsidiary companies.Priovant Therapeutics, a company within the Roivant Sciences family, announced positive results from its Phase 2 BEACON study evaluating brepocitinib for the treatment of cutaneous sarcoidosis. The study reported that 100% of patients receiving the 45 mg dose showed improvement, and the drug was well tolerated with no serious adverse events. This marks the first industry-sponsored placebo-controlled trial in this condition to report positive results, with plans to advance to a Phase 3 program in 2026.The promising clinical data for brepocitinib appears to have driven investor optimism, overshadowing the company's concurrent release of its third-quarter financial results, which included a net loss.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130252803","isCrawlerRequest":true}